ClinicalTrials.Veeva

Menu

Korean Multicenter Registry of EPIC Stent for Iliac Artery Disease: (K-EPIC Registry)

Yonsei University logo

Yonsei University

Status

Unknown

Conditions

Iliac Artery Disease

Treatments

Device: Epic stent (Boston Scientific)

Study type

Observational

Funder types

Other

Identifiers

NCT02698358
1-2015-0075

Details and patient eligibility

About

  • Prospective, single-arm, multi-center registry study
  • A total of 150 subjects with iliac artery disease who meet all inclusion and exclusion criteria will be included.
  • Patients will be followed clinically for 12 months after the procedure.
  • Duplex ultrasound, CT or catheter-based angiography follow-up according to participating hospital's protocol will be performed at 12 months.
  • Presence of stent fracture will be evaluated by plain radiography or fluoroscopy at 12 months.
  • Quality of life by standardized questionnaires (at baseline & at 1 & 12 months)

Enrollment

68 patients

Sex

All

Ages

19 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age 19 years of older

  2. Symptomatic peripheral artery disease:

    • Moderate or severe claudication (Rutherford category 2 or 3)
    • Critical limb ischemia (Rutherford category 4)
  3. Iliac artery lesions with stenosis > 50%

  4. ABI <0.9

  5. Patients with signed informed consent

Exclusion criteria

  1. Acute critical limb ischemia
  2. Severe critical limb ischemia (Rutherford category 5 or 6)
  3. Known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, cilostazol, or contrast agents
  4. In-stent restenosis lesions (Restenosis lesions without previously implanted stents are eligible to the enrollment)
  5. Bypass graft lesions
  6. Age > 85 years
  7. Severe hepatic dysfunction (> 3 times normal reference values)
  8. Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis
  9. LVEF < 40% or clinically overt congestive heart failure
  10. Pregnant women or women with potential childbearing
  11. Life expectancy <1 year due to comorbidity
  12. Untreated proximal inflow disease of aorta or the ipsilateral iliac arteries (more than 50% stenosis or occlusion)

Trial design

68 participants in 1 patient group

K-EPIC
Description:
Patients with femoropopliteal artery disease undergoing endovascular therapy using Epic stent (Boston Scientific).
Treatment:
Device: Epic stent (Boston Scientific)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems